世基生物醫學股份有限公司 Approved
最後更新時間 2025/07/10 , 09:17 PM
最後更新時間 2025/07/10 , 09:17 PM
負責人
Zhan,Fu-Hui
統一編號
27953682
成立日期
2005/09/28
資本額
NT$800,000,000
實收資本額
NT$504,650,000
股票代號
7595
電話
02-27985885
地址
4F, No. 17, Ln. 171, Sec. 2, Jiouzong Rd., Neihu Dist., Taipei City, 114, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Zhan,Fu-Hui Chairman 9.82% TAIWAN QIN YUE Co., Ltd.
Cai,Shi-Chen Director 9.82% TAIWAN QIN YUE Co., Ltd.
Xiao,Ce Director 9.82% TAIWAN QIN YUE Co., Ltd.
Xu,Ying-Zhou Director 22.14% LYMA TECH CO., LTD.
Li,Ying-Da Director 22.14% LYMA TECH CO., LTD.
Li,Jun-Yi Director 1.78%
Chen,Guan-Zhi Director 0.21%
Chen,Yi-Xiong Independent Director 0.00%
Chen,Chi-Ping Independent Director 0.00%
Chen,Yi-Rou Independent Director 0.00%
營業項目
  • Wholesale on a Fee or Contract Basis(451099)
  • Data Processing, Hosting and Related Activities(631299)
  • Wholesale of Chemical Materials and Chemical Products(462099)
  • Medical Test and Examination Activities(869100)
  • 公司歷程
  • Change Capital to 800,000,000
    2023/06/15
  • Change Person in Charge to Zhan,Fu-Hui
    2022/07/12
  • Change Capital to 680,000,000
    2021/09/15
  • Change Person in Charge to Chen,Jin-Ze
    2019/11/21
  • Change Person in Charge to You,Zhuo-Yuan
    2018/11/23
  • Change Person in Charge to Huang,Zhao-Xi
    2016/01/20
  • Change Person in Charge to Chen,Wen-Rang
    2015/07/13
  • Change Person in Charge to Wang,Zhi-Xiong
    2014/07/18
  • Change Capital to 500,000,000
    2012/05/25
  • 員工人數
    財務報表
    項目 2024 2023 2022
    Operating income 116,534 132,707 133,801
    Operating cost 75,063 90,166 89,074
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 41,471 42,541 44,727
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 41,471 42,541 44,727
    Operating expenses 126,696 101,726 89,178
    Other gain (loss), net - - -
    Operating profit (loss) -85,225 -59,185 -44,451
    Non-operating income and expenses 2,396 -13,445 1,746
    Net profit (loss) before tax -82,829 -72,630 -42,705
    Income tax expense (benefits) 35 16 11
    Net profit (loss) of ongoing business for the current period -82,864 -72,646 -42,716
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -82,864 -72,646 -42,716
    Other comprehensive profit (loss), net -12,177 1,997 242
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -95,041 -70,649 -42,474
    Net profit (loss) attributable to owners of parent company -82,864 -72,646 -42,716
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests 0 0 -
    Comprehensive profit (loss) attributable to owners of parent company -95,041 -70,649 -42,474
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests 0 0 -
    Basic earnings per share (yuan) -1 -1 0
    項目 2024 2023 2022
    Net cash inflow (outflow) from operating activities -44,822 -77,536 -23,466
    Net cash inflows (outflows) from investing activities 21,097 -657,433 4,899
    Net cash inflow (outflow) from financing activities 47,284 726,646 -9,180
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 250 -3 319
    Increase (decrease) in cash and cash equivalents in the current period 23,809 -8,326 -27,428
    Beginning balance of cash and cash equivalents 68,534 76,860 104,288
    Ending balance of cash and cash equivalents 92,343 68,534 76,860
    項目 2024 2023 2022
    Current asset 250,251 253,986 258,539
    Non-current asset 752,893 792,968 125,730
    Total asset 1,003,144 1,046,954 384,269
    Current liability 52,509 36,720 38,304
    Non-current liability 601,575 566,133 6,215
    Total liability 654,084 602,853 44,519
    share capital 504,650 504,650 434,650
    Equity - secruity token - 0 -
    capital reserve 105,000 105,000 0
    retained earning -251,336 -172,733 -100,087
    Other equity -9,254 7,184 5,187
    Treasury stock - 0 -
    Total equity attributable to owners of parent company 349,060 444,101 339,750
    Equity attributable to former owner of business combination under common control - 0 0
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - 0 0
    Total Equity 349,060 444,101 339,750
    Share capital awaiting retirement (unit: share) - - 0
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 6 8 781
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • PharmiGENE及世基生物醫學股份有限公司
  • PharmiGENE
  • 世基生物醫學股份有限公司標章
  • i-Gene
  • PHARM I GENE
  • Pharmigene
  • The PGx Engine
  • PHARMA GENE
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
    勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。